New Study Enrolling: RISE - Treating Ulcerative Colitis

AdventHealth Research Institute is the first in Central Florida to participate in the expansion phase of a clinical trial exploring a potential new oral immunotherapy treatment for mild to moderate ulcerative colitis. Called RISE-3750-01 and led by AdventHealth IBD Clinic Medical Director Jennifer Seminerio, MD, the study is evaluating the safety and tolerability of R-3750, which was designed to enhance the gut barrier, reduce inflammation and correct imbalance in the microbiota. Click below to learn more about this exciting study.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News

Conform Trial: Major Milestone Achieved

On August 8, 2025, our team successfully completed the very first implant day for the Conform Clinical Trial, enrolling and treating our first three patients with the Conformal CLAAS System for Left...